NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Juncell Therapeutics Co., Ltd.

Shanghai Juncell Therapeutics Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://juncell.com/

Last Round

Series B

Apr 1, 2024

Total Funding Raised

$100.12M

Company Overview

Shanghai Juncell Therapeutics Co., Ltd. is a biotechnology company that develops innovative tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tumor-infiltrating lymphocyteTIL therapycell therapysolid tumor treatmentimmunotherapycancer immunotherapygene-modified TILbiotechnologyclinical-stage biotechcell expansionnext-gen TILoncology R&Din vivo TILnon-viral gene modification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Juncell Therapeutics Co., Ltd. Comparables

Compare Shanghai Juncell Therapeutics Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Juncell Therapeutics Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Shanghai Juncell Therapeutics Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 1, 2024
Series A ExtensionJan 15, 2022
Series AFeb 26, 2021
Pre SeedFeb 21, 2020

Shanghai Juncell Therapeutics Co., Ltd. Investors

Notable investors and investment history

Shanghai Juncell Therapeutics Co., Ltd. investors
InvestorRounds
Kaitai CapitalSeries A Extension, Series B, Series B Extension, Series A
YuanBio Venture CapitalSeries A Extension, Series B Extension
ALAN Asset ManagementSeries A Extension
Medfine CapitalSeries A
Oriza Seed Venture CapitalSeries A Extension, Series C, Series B Extension, Pre Seed

Shanghai Juncell Therapeutics Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Juncell Therapeutics Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Juncell Therapeutics Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range1
Year Founded2019
Last FundingApr 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.